Recursion Pharmaceuticals Shares Rise Following FDA Agreement on Phase 3 Trial Design

Recursion Pharmaceuticals (RXRX) shares rose over 5% following an announcement that the U.S. Food and Drug Administration has agreed to the company's design for Phase 3 clinical trials of REC-4881. The drug, an oral MEK1/2 inhibitor, is intended to treat familial adenomatous polyposis (FAP). This represents a significant milestone as REC-4881 is currently the most advanced candidate in the company's internal pipeline. The news serves as a validation of Recursion’s AI-powered drug discovery platform, which allows for virtual pre-testing of molecules. While the FAP market is relatively small, the successful progression to late-stage trials demonstrates the practical application of the company's technology. Analysts note that while the move is positive, much of the price action may be a technical rebound following a significant recent decline in share value.

By James Brumley · Motley Fool ·

Recursion Pharmaceuticals Shares Rise Following FDA Agreement on Phase 3 Trial Design

Tickers: $RHHBY $RXRX $SNY

Topics: AI in drug discovery Drug development FDA approval for clinical trial design Phase 3 trials

Read the full article at Motley Fool

Part of the story Recursion Pharmaceuticals Shares Rise Following FDA Alignment on REC-4881 Phase 3 Design (2 articles)

More Health news